Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, stated: "People with diabetes who rely on these medications should not have to compete with demand driven by cosmetic use" 6
The benefit on weight, blood sugar, and cardiovascular risk is well established in the large trials, and the pancreatitis risk in those same trials is low and not clearly elevated
This damage comes from both internal and external factors
The molecule was first identified and studied by the Sikiric research group in Croatia starting in the early 1990s, and the bulk of the preclinical evidence base comes from more than three decades of rat and rodent studies showing consistent tissue-repair, anti-inflammatory, and gastroprotective effects
A secondary analysis of clinical trial data found that up to 40% of weight lost on semaglutide can be lean mass -- muscle and bone -- rather than fat, particularly in women and older adults